Aviceanna.AI has announced that its medical imaging artificial intelligence (AI) tool, CINA Head, has qualified for the new technology add-on payment (NTAP) recently approved by the Centers for Medicare and Medicaid Services (CMS).
CINA Head analyses computer tomography angiogram (CTA) images of the brain taking during acute settings, and notifies clinicians when it identifies a suspected large vessel occlusion (LVO), potentially reducing time to treatment according to the company. Additionally, CINA Head has been approved by the US Food and Drug Administration (FDA) for use in neurovascular emergencies for the detection of intracranial haemorrhages (ICHs).
According to the company, CINA Head uses a combination of deep learning and machine learning technologies in order to automatically detect and prioritize acute ICG and LVO cases from CTA images in less than 20 seconds, alerting clinicians.
The NTAP award is available for radiological computer-assisted triage and notification software systems like CINA Head.
Peter Chang, Radiologist and co-founder of Avicenna.AI, California, USA, commented, “AI-enabled CT stroke triage, specifically with LVO detection, is the first deep learning tool to receive the CMS NTAP designation and is eligible for up to $1040 of reimbursement. CMS only grants NTAP designation to promote the adoption of new technology that provides substantial clinical improvement over standard of care. This will help accelerate the innovation and adoption of deep learning technology by aligning the incentives of both software developers and clinical providers.”